Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3174998 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT02528357Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2015
- Primary completion
- Apr 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of gsk3174998 in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), renal cell carcinoma (RCC) and 5 more (3 arms), sponsored by GSK. Primary endpoints: Adverse Events at 33 weeks, Dose Limiting Toxicities at 28 days and 4 more. Started Sep 2015; status: completed.
02
Drugs
gsk3174998
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)renal cell carcinoma (RCC)melanomabladder cancer
Beyond the preview
Go deeper on NCT02528357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528357.